Evommune (EVMN) Total Non-Current Liabilities (2024 - 2025)
Evommune (EVMN) posted quarterly Total Non-Current Liabilities of $10.4 million for Q3 2025, down 62.77% quarter-over-quarter from $28.0 million in Q4 2024.
Powered by 
Analysis
Evommune (EVMN) Total Non-Current Liabilities (2024 - 2025) Analysis & Trends
Evommune (EVMN) has reported Total Non-Current Liabilities for 2 consecutive years, with $10.4 million the latest figure, recorded in Q3 2025.
- In Q3 2025, Total Non-Current Liabilities changed N/A year-over-year to $10.4 million; the TTM figure through Sep 2025 stood at $10.4 million (changed N/A YoY), while the FY2024 annual figure was $28.0 million, changed N/A from the prior year.
- Total Non-Current Liabilities retreated to $10.4 million in Q3 2025 per EVMN's latest filing, from $28.0 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $28.0 million in Q4 2024 and bottomed at $10.4 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 3.92 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 1.53 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 1.88 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 4.20 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 9.32 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 1.17 Bn |
| 10 | Evommune | 445.19 Mn | 244.40 Mn | - | - |